secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pasithea Therapeutics Corp. (KTTA)
CIK:        0001841330
Form:       8-K
Filed at:   2024-09-26T23:59:59+00:00
Accession:  0001213900-24-081982
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pasithea reports positive Phase 1 data for PAS-004: no TRAEs, prolonged stable disease in colon cancer patient
--------------------------------------------------------------------------------

- No treatment-related adverse events or dose-limiting toxicities observed in first 2 cohorts (n=6); no rash or GI toxicity.
- Heavily pre-treated stage 3 colon cancer patient (BRAF K601E) achieved prolonged stable disease, remains on drug into 6th cycle.
- Half-life ~70 hours supports once-daily or less frequent oral dosing; steady-state Cmax/Cmin ratio of 1.2.
- Systemic exposure at steady-state enables constant target inhibition while avoiding peak plasma toxicities.
- Safety review completed; cohort 3 dosing initiated at 8 mg with protocol amendment to increase dosing schedule.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841330/000121390024081982/0001213900-24-081982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841330/000121390024081982/ea0215731-8k_pasithea.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-081982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer